Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth?
Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth?
With $2.6 billion in cash and investments, Jazz maintains $500 million in undrawn credit. Jazz repaid $575 million in senior notes due 2024, illustrating its disciplined debt management. The company reported that its financial and product strategies are expected to drive growth in critical therapeutic areas, enhancing long-term shareholder value.Jazz Pharmaceuticals plc (NASDAQ:JAZZ) reported record third-quarter revenue of $1.05 billion on Wednesday afternoon, up 14% year-over-year, propelled by strong sales of key therapies like Xywav, Epidiolex and Rylaze.
爵士製藥公司（納斯達克：JAZZ）週三下午報告稱，第三季度營業收入創下了10.5億美元的記錄，同比增長14％，主要受到Xywav、Epidiolex和Rylaze等關鍵療法銷售強勁推動。
The gross margin held steady at 89%. CEO Bruce Cozadd said Jazz remains "confident in its revenue guidance of $4.0 to $4.1 billion" for the full year.
毛利率保持在89％。首席執行官Bruce Cozadd表示，爵士製藥對全年4,000萬至41億美元的收入指引保持「充滿信心」。
- Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. You can't afford to miss out if you're serious about the business.
- 在Benzinga獲取獨家分析，並每天免費獲得關於大麻業務和市場的頭條新聞。立即訂閱我們的通訊，認真對待業務，您不容錯過。
Net Income Boosted By Adjusted Expenses
通過調整費用提振淨利潤
The company generated net income in the range of $430 to $550 million, increasing its GAAP EPS guidance to between $6.70 and $8.50. Jazz also adjusted its R&D expense forecast, reflecting strategic prioritization within its pipeline, notably the anticipated fourth-quarter launch of zanidatamab for 2L BTC, a significant step in oncology.
該公司淨利潤在4.3億至55000萬美元的區間內，將其GAAP每股收益指引提高至6.70至8.50美元。爵士製藥還調整了研發支出預測，反映了其在管線中的戰略優先級，特別是預期第四季度推出2L BTC的zanidatamab，這是腫瘤學領域的一大進展。
Liquidity And Debt Management
流動性和債務管理
With $2.6 billion in cash and investments, Jazz maintains $500 million in undrawn credit. Jazz repaid $575 million in senior notes due 2024, illustrating its disciplined debt management. The company reported that its financial and product strategies are expected to drive growth in critical therapeutic areas, enhancing long-term shareholder value.
憑藉26億美元的現金和投資，爵士製藥保持着50000萬美元的未動用信貸額度。爵士製藥償還了到期日爲2024年的57500萬美元的優先票據，展現了其嚴謹的債務管理。該公司報告稱，其財務和產品戰略預計將推動關鍵治療領域的增長，提升長期股東價值。
Price Action: Jazz Pharmaceuticals shares remained relatively stable, closing at $111.55 with a slight gain of 0.11%
股價走勢：爵士製藥股價保持相對穩定，收盤價爲111.55美元，微漲0.11％。
譯文內容由第三人軟體翻譯。
